Grant ID DP170043
Awarded On August 16, 2017
Title Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multi-Virus Specific T cells
Program Product Development Research
Award Mechanism Texas Company Product Development Awards
Institution/Organization ViraCyte LLC
Principal Investigator/Program Director Ann Leen
Cancer Sites Leukemia, Lymphoma
Contracted Amount $8,998,067
Lay Summary

Many patients with cancer are cured by a stem cell transplant from a donor's bone marrow, umbilical cord blood, or peripheral blood. However, because these patients must endure a period of months before their immune system recovers, severe viral infections afflict over 70% of patients following transplant. These viral infections cause pain, organ damage, prolonged hospitalization, and even death. In fact, viral infections are now the most common severe complication related to stem cell transplantation. Because of the risk of infection, many other cancer patients cannot receive a transplant, and thus lose their best hope for cure.

ViraCyte has developed revolutionary new T-cell therapies th...

Read More